101 publications

Name Date Type Actions

[VIDEO ]Présentation des résultats 2020 - french

Présentation analystes & investisseurs - 1er avril 2021

 		01/04/2021 Annual Report

[VIDEO] Présentation des résultats semestriels 2021 - french

Présentation analystes & investisseurs - 29 juillet 2021

 		29/07/2021 Half Year Report

[Video] Présentation des résultats semestriels 2022 - french

Présentation analystes & investisseurs - 15 septembre 2022

 		29/07/2021 Half Year Report

2012 ANNUAL RESULTS

SFAF Meeting March 27, 2013

 		28/03/2013 Annual Report

2012 sales up 5.0%

Lure (France), January 24, 2013 – Vétoquinol posted 2012 sales of €298.3 million, up 5.0% compared to the previous year. At constant exchange rates, annual sales increased by 3.0%.

 		24/01/2013 Public releases

2012, return to growth

Lure, March 26, 2013 – The Vétoquinol Board meeting of March 7, 2013 reviewed the Group's business and approved the 2012 financial statements.

 		26/03/2013 Public releases

2013 3rd quarter sales show organic growth

Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates.

 		24/10/2013 Public releases

2020 annual results 2020 sales: €427.5m (up 8.0% as reported)

EBIT before depreciation of assets arising from acquisitions: €65.3m (up 33.5%)
Net income - Group share: €19.2m (4.5% of sales)
Cash flow: €92.2m

 		01/04/2021 Public releases

2020 sales: €427.5M (up 8.0% as reported, up 10.9% at constant exchange rate) essentials sales: €220.6M (up 15.7% as reported, up 17.3% at constant exchange rate)

Vetoquinol CEO Matthieu Frechin said: “2020 was an exceptional year on a number of counts. Above all, it is important to pay tribute to our teams, whose hard work and exemplary dedication allowed us to manage the impact of the health crisis. Year on year, we achieved double-digit sales growth at constant exchange rates, driven by our Essentials products. This momentum accounts for additional sales of €43 million (at constant exchange rates). We also completed a major acquisition in the form of the Drontal® and Profender® product ranges, entailing three structural effects for Vetoquinol: a scale effect, a product mix effect in the Essentials range and potential extensions, the first of which has been confirmed in January 2021 for the Australian market. We are optimistic for our business outlook in 2021, while being vigilant in relation to the global sanitary situation.”

 		21/01/2021 Public releases

2020 Universal registration document

2020 universal registration document including the Annual Financial Report

 		28/04/2021 Reference document